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Familial amyloidotic polyneuropathy (FAP) is an autoso-mal dominant inherited form of amyloidosis associatedwith a mutant form of a protein called transthyretin. Theabnormal protein results from a single point mutation in
the gene encoding transthyretin (18q). More than 70 mutations
have been described, the most common of which is Met30 (Por-
tuguese variant), which usually presents as a rapidly progressive
autonomic neuropathy in the second and third decades of life. This
genotype is not associated with cardiomyopathy, and it is cured by
means of liver transplantation alone. The second most prevalent is
the mutation Tyr 77 (German variant), which is typically associ-
ated with rapidly progressive autonomic neuropathy and cardio-
myopathy in the fifth or sixth decades of life, leading to death
within 5 to 10 years. Combined heart and liver transplantation is
indicated when both organs are involved by the same pathologic
process because one organ causes damage to the other organ.
Although isolated liver transplantation halts the progression of the
autonomic neuropathy, cardiomyopathy usually worsens after
transplantation because the transthyretin synthesized by the donor
liver continues to precipitate on the abnormal transthyretin already
deposited in the myocardium.1 On the other hand, if cardiac
transplantation alone is performed, the patient does not recover
because the liver continues to produce the mutated protein.2 There-
fore the therapy of choice is transplantation of the injured organ
(the heart) and the organ that produces the injury (the liver).
Materials and Methods
PATIENT 1. A 60-year old man underwent stress test electrocardi-
ography to assess his fitness for sport, but during the test, atrial
fibrillation arose. The cardiologist performed echocardiography,
which revealed the increased thickness of the walls of the ventri-
cles, small ventricular chambers, dilated atria, and thickening of
the interatrial septum, demonstrating also a granular sparkling
texture. Six months later, the patient was admitted to the hospital
because of cardiac failure, diarrhea, and nocturnal paresthesia. The
electromiography revealed the denervation of the anterior tibial
muscle and a lower speed of conduction in the left sural muscle.
The patient was transplanted 18 months after onset of the disease.
PATIENT 2. A 45-year old man complained of a 2-year history of
easy fatigability on prolonged walking. The clinical history could
be traced back to when the patient was 43 years old. At that time,
he had already noticed constipation alternating with diarrhea and
occasional lipothymias. Echocardiography demonstrated a typical
speckling pattern consistent with amyloid deposition within the
myocardium, and this was confirmed by means of subsequent
endomyocardial biopsy. An abdominal fat biopsy also suggested
systemic amyloidosis. Abnormal transthyretin protein was de-
tected in the serum, which is consistent with the diagnosis of FAP.
The patient underwent transplantation 2 years after the onset of
symptoms.
PATIENT 3. A 50-year-old man presented with a 4-year history of
asthenia and reduced pinprick and light-touch sensation in both
feet. Nerve conduction studies revealed an early sensorimotor
peripheral neuropathy consistent with amyloid neuropathy. Echo-
cardiography demonstrated a typical pattern consistent with amy-
loid deposition within the myocardium, and this was confirmed by
means of subsequent endomyocardial biopsy. Abnormal transthy-
retin protein was detected in the serum, which is consistent with
the diagnosis of amyloid polyneuropathy. The patient underwent
transplantation 5 years after the onset of the first symptoms.
DNA study on the white blood cells of the 3 patient revealed
the Glu 89 mutation.
Operative Technique
The hepatic and cardiac steps of the operation were done by the
respective surgical teams. The first step of the operation was the
implantation of the heart of the donor into the recipient. After the
heart transplantation was complete, the chest was left open and
covered with a sterile drape (Steri-Drape; 3M Company, St Paul,
Minn). The second step was the liver implantation. After all
hepatic vascular anastomoses had been completed, the cardiac
team returned to control residual bleeding in the chest, and all
incisions were closed.
Postoperative Course
PATIENT 1. The course was good from the first postoperative hours.
The patient was discharged from the intensive care unit on the fifth
postoperative day. At the seventh postoperative day, a rejection of
the cardiac graft was diagnosed by means of an endomyocardial
biopsy (grade 3A), and the hepatic biopsy also confirmed liver
rejection (grade 2) after an increase in serum transaminase levels.
Therefore, corticosteroids (500 mg  3/day) were used as antire-
jection therapy, and the subsequent liver and cardiac biopsies
demonstrated a frank regression of the rejection. The patient was
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discharged on postoperative day 22 in very good condition. Cur-
rently, the patient is well and working full time. His liver chem-
istry test results are within normal limits, and the endomyocardial
biopsy revealed no evidence of rejection or amyloid deposits.
PATIENT 2. The operative course of this patient was complicated
by bowel ischemia (caused by a venous thrombosis), for which he
was treated with a right hemicolectomy and ileostomy at the end of
the transplantation. The patient was discharged from the intensive
care unit on postoperative day 13 with good heart and liver
function. The postoperative course of this patient was complicated
by malabsorption syndrome until the intestinal continuity was
restored. He was discharged from the hospital on postoperative day
120. The patient’s liver chemistry test results were normal, and the
echocardiogram showed a very good cardiac performance. Cur-
rently, he has normal liver function, and the endomyocardial
biopsy revealed no evidence of rejection or amyloid deposits.
PATIENT 3. The postoperative course of this patient was char-
acterized by a re-exploration for bleeding. An endomyocardial
biopsy revealed a grade 1B rejection on postoperative day 18 that
was immediately treated with antithymocyte globulins. Liver
chemistry test results were within normal limits, but from postop-
erative day 3, the patient became anuric with high levels of
creatinine (8 mg/dL), and therefore he underwent dialysis every
other day. The pharyngeal tampon was positive for Candida albi-
cans, and Aspergillus fumigatus and Pseudomonas aeruginosa
were identified in the bronchial aspirate. Chemotherapy was
started, but the patient died on postoperative day 60 as a result of
septic shock.
Discussion
Including our 3 patients, there are 7 patients worldwide who
underwent combined heart and liver transplantation because of
FAP (Table 1). The patients presented the pattern of restrictive
cardiomyopathy.
Although disease progression is halted with liver transplanta-
tion alone, it has been suggested that progression of FAP is
possible after transplantation. Dubrey and colleagues3 recently
reported that some patients with FAP showed continuous left
ventricular wall thickening after liver transplantation, with a con-
comitant trend toward deterioration of ventricular function. This
study also showed that ventricular wall thickening was more
frequent in patients with FAP who had undergone transplantation
and who had non-Met-30 transthyretin mutations.
Similarly, Pomfret and coworkers4 recently showed that those
patients with echocardiographic evidence of ventricular wall thick-
ening before liver transplantation progressed postoperatively de-
spite neurologic improvement. Dubrey and colleagues3 suggested
that amyloid fibrils already present, for instance, in the heart of the
transplant recipient could act as a nidus for nonhepatic sources of
mutant transthyretin or for the deposition of normal transthyretin
produced by the transplanted liver. Although there is concern that
amyloidosis is a systemic disease that might result in both recur-
rence in the donor heart and progression of the disease in other
organs, the extremely poor prognosis of these patients raised the
possibility of heart transplantation as a potential therapeutic pro-
cedure. However, a later multicenter survey suggested that initial
enthusiasm was premature because the patients had restrictive
cardiomyopathy.5
Actually, 5 of the 7 patients who underwent heart and liver
transplantation are alive. There was not a progression or recurrence
of the disease with standard immunosuppressive therapy, and these
patients have a very good quality of life. Therefore, according to
our experience and literature data, we believe that combined heart
and liver transplantation should be considered an efficacious ther-
apeutic option for patients with FAP.
We thank Dr Giovanni Grillone, Dr Carlo Alberto Tassinari,
and Professor Antonino Cavallari for their collaboration in the
management of these patients and for their technical assistance in
the writing of this article.
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TABLE 1. Previous experiences
City Hospital Mutation In-hospital death Actuarial survival
Pittsburgh Presbyterian University Hospital ALA 60 No Yes
London King’s College Hospital TYR 77 No No (3 y later)
Mainz Der Johannes Gutenberg Universita¨t LEU 33 No Yes
Auckland Green Lane Hospital TYR 77 No Yes
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